Mavyret Is a Leading Drug in AbbVie’s HCV Franchise
AbbVie (ABBV) reported global HCV (hepatitis C) franchise sales worth $862 million in the third quarter, a YoY (year-over-year) rise of more than 100% on both an operational and a reported basis. The company reported HCV sales of $444 million in the US market, a YoY rise of more than 100%. AbbVie also reported HCV sales of $418 million in international markets in the third quarter, YoY rises of 94.5% on a reported basis and 95.6% on an operational basis.